Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Author:

Melé‐Ninot Gemma1ORCID,Curto‐Barredo Laia2,Bonfill‐Ortí Montserrat3,Expósito‐Serrano Vicente4,Munera‐Campos Mónica5ORCID,Figueras Nart Ignasi2,Riquelme‐Mc Loughlin Constanza6,Gómez‐Armayones Sara6,Spertino Jorge7,Serra‐Baldrich Esther7

Affiliation:

1. Dermatology Department Hospital Universitari Sagrat Cor, Grupo Quirónsalud Barcelona Spain

2. Dermatology Department Hospital del Mar‐Institut Mar d'Investigacions Mèdiques Barcelona Spain

3. Dermatology Department Hospital de Bellvitge Barcelona Spain

4. Dermatology Department Hospital Universitari Parc Taulí Barcelona Spain

5. Dermatology Department, Hospital Universitari Germans Trias i Pujol Universitat Autònoma de Barcelona, Germans Trias i Pujol Research Institute (IGTP) Barcelona Spain

6. Dermatology Department Hospital Clínic Barcelona Spain

7. Dermatology Department Hospital de la Santa Creu i Sant Pau Hospital Barcelona Spain

Abstract

AbstractBackgroundDupilumab has shown to be an effective and safe treatment for patients with moderate‐to‐severe atopic dermatitis (AD).ObjectiveTo evaluate the predictive factors of response (PRF) in patients with moderate‐to‐severe AD treated with dupilumab.MethodsObservational, retrospective and multicentre study conducted on adult patients diagnosed with moderate‐to‐severe AD treated with dupilumab, with a post‐treatment follow‐up of at least 16 weeks. The primary endpoints were EASI‐75 and the IGA scale at week 52.ResultsA total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD‐predominant phenotypes were flexural eczema (45.3%), head‐and‐neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI‐75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI‐75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049).ConclusionsDupilumab was an effective treatment in patients with moderate‐to‐severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI‐75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.

Publisher

Wiley

Subject

Dermatology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3